Skip to main content

Table 2 Afatinib starting dose, dose adjustment and optimal dose and treatment of baseline brain metastases

From: Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Treatment Pattern and Outcome Total number of patients
(n = 85)
Afatinib starting dose, No. (%)
 40 mg once daily 45 (52.9)
 30 mg once daily 30 (35.3)
 25 mg once daily 3 (3.5)
 20 mg once daily 7 (8.2)
Afatinib dose adjustment, No. (%)
 Starting dose maintained 49 (57.6)
 Dose increased 10 (11.8)
 Dose reduced 26 (30.6)
Afatinib optimum dose, No. (%)
 50 mg once daily 4 (4.7)
 40 mg once daily 30 (35.3)
 30 mg once daily 30 (35.3)
 25 mg once daily 12 (14.1)
 20 mg once daily 9 (10.6)
Brain metastasis treatment, No. (%)
 No brain metastases 60 (70.6)
 Afatinib alone 4 (4.7)
 Afatinib with surgery or radiotherapy 21 (24.7)